Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.36 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6398864 | 0.93 | IGF1R (0.38) | ADRB2ESR1ESR2LTA4H | |
| SCHEMBL6399205 | 0.88 | ADRB2 (0.40) | ADRB2ESR1ESR2ANPEPERAP2 | |
| SCHEMBL6401616 | 0.87 | ANPEP (0.43) | ADRB2ANPEPERAP2ERAP1 | |
| SCHEMBL6401672 | 0.86 | ESR1 (0.40) | ADRB2ESR1ESR2 | |
| SCHEMBL6402018 | 0.81 | IGF1R (0.38) | ADRB2ESR1ESR2LTA4H | |
| SCHEMBL6403048 | 0.81 | MGLL (0.41) | ADRB2ANPEPERAP2ERAP1 | |
| SCHEMBL6398713 | 0.80 | SLC28A3 (0.40) | ADRB2ESR1ESR2ANPEPERAP2 | |
| SCHEMBL6401423 | 0.79 | ADRB2 (0.35) | ADRB2ESR1ESR2ANPEPERAP2 | |
| SCHEMBL6397802 | 0.79 | MEN1 (0.37) | ADRB2ESR1ESR2ANPEPERAP2 | |
| SCHEMBL6394675 | 0.77 | ENPP2 (0.39) | ANPEPERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187195-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | PEERCE BRIAN E (US) | 2005-08-25 | — | — | US | disclosed |
| US-20030162753-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187195-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | SLC34A3, SLC34A1, SLC34A2 | ADRB2 2200/4885ESR1 2885/4885ESR2 2416/4885 |
| US-20030162753-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | SLC34A3, SLC34A1, SLC34A2 | ADRB2 2200/4885ESR1 2885/4885ESR2 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.